Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium selenite in patients with advanced carcinoma: SECAR 1c
2025-522798-13-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium selenite in carcinoma and cancer, sponsored by Karolinska University Hospital. Primary endpoint: Optimal dose and clinical response without dose-limiting toxicity (DLT). Planned start Dec 2025; status: authorised.
02
Drugs
sodium selenite
03
Conditions
carcinomacancer
Beyond the preview
Go deeper on 2025-522798-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522798-13-00.